EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia Silences Neuroprotective Gene Programs — Reversible by EZH2 Inhibitors

The proposed hypothesis posits that in senescent microglia of amyotrophic lateral sclerosis (ALS) patients, the Polycomb Repressive Complex 2 (PRC2) catalytic subunit EZH2 deposits trimethylation of histone H3 at lysine 27 (H3K27me3) across the genomic loci of neuroprotective genes BDNF, GRN, TREM2, and MerTk, leading to their transcriptional silencing. According to this model, pharmacologic inhibition of EZH2 would remove the repressive histone mark and restore expression of these protective factors, thereby mitigating neurodegeneration.

Supporting evidence from non‑ALS contexts suggests that EZH2 activity can regulate microglial inflammation and that its inhibition may reverse inflammatory gene programs. In a murine model of ischemic brain injury, EZH2 was shown to rise in activated microglia, and the selective EZH2 inhibitor DZNep suppressed the microglial inflammatory program, indicating that EZH2 inhibition can attenuate pro‑inflammatory signaling in microglia (PMID 31202798). Further work in a stroke model demonstrated that EZH2‑driven H3K27me3 amplifies neuroinflammation through the SOCS3/TRAF6/NF‑κB signaling axis and that this amplification can be diminished by EZH2 inhibition (PMID 32933418). Additionally, studies in stressed mice revealed that EZH2 regulates age‑linked vulnerability to microglial neuroinflammation, implying that the enzyme influences inflammatory susceptibility in a context‑dependent manner (PMID 32553389). A direct mechanistic link to ALS comes from research showing that PRC2/H3K27me3 binds C9orf72 repeat RNA, linking Polycomb repression machinery to an ALS‑relevant repeat‑expansion mechanism (PMID 31048495).

These findings, however, are derived primarily from stroke, stress, or other neuronal injury paradigms and therefore may not fully recapitulate the microglial landscape in ALS. Consequently, extrapolation to ALS microglia must be approached with caution.

Evidence that counters the straightforward therapeutic expectation highlights the context‑dependent nature of EZH2 in the central nervous system. In a CNS tumor microenvironment, suppression of EZH2 shifted microglia toward a pro‑inflammatory M1 phenotype, suggesting that EZH2 inhibition could paradoxically enhance neuroinflammation rather than restore protective gene expression (PMID 29132376). Moreover, a study that attempted to detect specific EZH2‑mediated H3K27me3 spreading over BDNF, GRN, TREM2, and MerTk in human ALS tissue reported a null result, indicating that such epigenetic spreading has not been directly demonstrated in patient samples (PMID 28257897).

Collectively, the extant literature suggests that EZH2‑dependent H3K27me3 may contribute to inflammatory gene silencing in microglia, but the direction and magnitude of this effect appear context‑dependent. While EZH2 inhibitors hold theoretical therapeutic potential for ALS by potentially restoring neuroprotective gene expression, their efficacy and safety will require careful evaluation of microglial phenotypes, confirmation of target‑gene demethylation in ALS‑specific models, and validation in human tissue. Further studies employing ALS‑relevant cellular and animal models, as well as human post‑mortem analysis, are needed to clarify whether EZH2 inhibition will indeed restore BDNF, GRN, TREM2, and MerTk expression or inadvertently amplify neuroinflammation.